InvestSMART

Clinuvel Pharmaceuticals Limited (ASX: CUV) - Announcements

Current share price for CUV : $8.240 0.01 (0.12%)+

ASX company news and announcements for Clinuvel Pharmaceuticals Limited (CUV) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Clinuvel Pharmaceuticals Limited (CUV) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Clinuvel Pharmaceuticals Limited (CUV), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Clinuvel Pharmaceuticals Limited (CUV)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$416 Update - Notification of buy-back - CUV 6 May 2024 9:18AM $14.860 $8.240 fallen by 44.55%
$416 Update - Notification of buy-back - CUV 3 May 2024 9:01AM $14.860 $8.240 fallen by 44.55%
$416 Syd Capital Markets Briefing Presentation 1 May 2024 9:18AM $15.050 $8.240 fallen by 45.25%
$416 SCENESSE European Orphan Drug Designation for XP 29 Apr 2024 9:24AM $14.570 $8.240 fallen by 43.45%
$416 Notification of cessation of securities - CUV 29 Apr 2024 9:18AM $14.570 $8.240 fallen by 43.45%
$416 Update - Notification of buy-back - CUV 29 Apr 2024 9:14AM $14.570 $8.240 fallen by 43.45%
$416 Ceasing to be a substantial holder 26 Apr 2024 8:19AM $14.990 $8.240 fallen by 45.03%
$416 CLINUVEL expands global leadership team 22 Apr 2024 9:27AM $14.380 $8.240 fallen by 42.70%
$416 Change to executive management 15 Apr 2024 10:01AM $15.170 $8.240 fallen by 45.68%
$416 Update - Notification of buy-back - CUV 12 Apr 2024 9:04AM $15.280 $8.240 fallen by 46.07%
$416 Update - Notification of buy-back - CUV 10 Apr 2024 9:16AM $15.250 $8.240 fallen by 45.97%
$416 Update - Notification of buy-back - CUV 9 Apr 2024 9:02AM $15.610 $8.240 fallen by 47.21%
$416 Becoming a substantial holder 9 Apr 2024 8:20AM $15.610 $8.240 fallen by 47.21%
$416 Notification of cessation of securities - CUV 4 Apr 2024 9:54AM $16.180 $8.240 fallen by 49.07%
$416 CLINUVEL Newsletter II - March 2024 20 Mar 2024 9:06AM $13.770 $8.240 fallen by 40.16%
$416 Update - Notification of buy-back - CUV 18 Mar 2024 2:45PM $14.140 $8.240 fallen by 41.73%
$416 Notification of buy-back - CUV 14 Mar 2024 10:55AM $13.250 $8.240 fallen by 37.81%
$416 CLINUVEL initiates on market share buy-back program 14 Mar 2024 10:51AM $13.250 $8.240 fallen by 37.81%
$416 New case of SCENESSE efficacy in vitiligo presented at AAD 11 Mar 2024 8:55AM $13.340 $8.240 fallen by 38.23%
$416 SCENESSE Presented at American Academy of Dermatology 8 Mar 2024 9:36AM $13.350 $8.240 fallen by 38.28%
$416 Ceasing to be a substantial holder 5 Mar 2024 8:04PM $13.970 $8.240 fallen by 41.02%
$416 SCENESSE provides photoprotection in variegate porphyria 4 Mar 2024 9:51AM $13.920 $8.240 fallen by 40.80%
$416 Becoming a substantial holder 28 Feb 2024 8:05AM $13.420 $8.240 fallen by 38.60%
$416 Final Director's Interest Notice 27 Feb 2024 1:10PM $13.410 $8.240 fallen by 38.55%
$416 Half Year Results Webinar Recording 23 Feb 2024 10:01AM $14.580 $8.240 fallen by 43.48%

176 - 200 of 872 results

Page 8 of 35

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.